Photo from wikipedia
In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1… Click to show full abstract
In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1 treatment resulted in a 62% response rate in patients with metastatic melanoma, accompanied by enhanced T cell infiltration in virus-injected lesions.
Keywords:
converting cold;
cold hot;
combining immunotherapies;
tumors combining;
hot tumors
Journal Title: Cell
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cell
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!